Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials

Author(s): Ronan J. Kelly, Ariel Lopez-Chavez, Eva Szabo

Journal Name: Current Drug Targets

Volume 12 , Issue 13 , 2011

Become EABM
Become Reviewer


Preclinical models and data from clinical trials suggest that cancer is a preventable disease. However, demonstration of a preventive effect requires large phase III clinical trials of long duration and involves many thousands of participants. The decision to proceed with phase III studies therefore must be informed by robust efficacy and safety data. This requires a systematic review of all available preclinical, epidemiological, and clinical data, along with a mechanistic understanding of the biology of the disease under study. In this review we identify the issues that are critical to decision-making prior to embarking on late phase prevention clinical trials and provide a framework for making such decisions.

Keywords: cancer, chemoprevention, clinical trials, carcinogenesis, efficacy, EGFR, safety, oncologic, phase III trials, NSAID

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [1983 - 1988]
Pages: 6
DOI: 10.2174/138945011798184173
Price: $65

Article Metrics

PDF: 10